These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 37403043)
1. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma. Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043 [TBL] [Abstract][Full Text] [Related]
2. 5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas. Zhang J; Wang N; Wu J; Gao X; Zhao H; Liu Z; Yan X; Dong J; Wang F; Ba Y; Ma S; Jin J; Du J; Ji H; Hu S Front Immunol; 2022; 13():844778. PubMed ID: 35309316 [TBL] [Abstract][Full Text] [Related]
3. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma. Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z Front Genet; 2022; 13():903117. PubMed ID: 35692827 [No Abstract] [Full Text] [Related]
4. m6A- and m5C- modified lncRNAs orchestrate the prognosis in cutaneous melanoma and m6A- modified LINC00893 regulates cutaneous melanoma cell metastasis. Shi HZ; Tian CC; Wu MY; Ma L; Sun JF; Chen H Skin Res Technol; 2024 Jul; 30(7):e13842. PubMed ID: 38965799 [TBL] [Abstract][Full Text] [Related]
5. Identification of m6A/m5C-related lncRNA signature for prediction of prognosis and immunotherapy efficacy in esophageal squamous cell carcinoma. Wang J; Ren H; Xu C; Yu B; Cai Y; Wang J; Ni X Sci Rep; 2024 Apr; 14(1):8238. PubMed ID: 38589454 [TBL] [Abstract][Full Text] [Related]
6. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma. Wu ZY; Shi ZY Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162 [TBL] [Abstract][Full Text] [Related]
7. Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma. Huang F; Wang X; Zhong J; Chen H; Song D; Xu T; Tian K; Sun P; Sun N; Qin J; Song Y; Ma W; Liu Y; Yu D; Meng X; Jiang C; Xuan H; Qian D; Cai J Cancer Cell Int; 2023 Aug; 23(1):156. PubMed ID: 37542290 [TBL] [Abstract][Full Text] [Related]
8. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas. Li Y; Li X; Yu Z Front Oncol; 2023; 13():1177120. PubMed ID: 37228500 [TBL] [Abstract][Full Text] [Related]
9. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients. He Y; Ye Y; Tian W; Qiu H Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662 [No Abstract] [Full Text] [Related]
10. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer. Liu Y; Wang T; Fang Z; Kong J; Liu J J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma. Chen Z; Zhang W; Yan Z; Zhang M Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574 [TBL] [Abstract][Full Text] [Related]
12. N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients. Tu Z; Wu L; Wang P; Hu Q; Tao C; Li K; Huang K; Zhu X Front Cell Dev Biol; 2020; 8():642. PubMed ID: 32793593 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related]
14. Prognostic signature and immune landscape of 5-methylcytosine-related long non-coding RNAs in gastric cancer. Song Q; Wu J; Wan H; Fan D Heliyon; 2024 Sep; 10(18):e37290. PubMed ID: 39323814 [TBL] [Abstract][Full Text] [Related]
15. Identification of m6A/m5C/m1A-associated LncRNAs for prognostic assessment and immunotherapy in pancreatic cancer. Huang Y; Zhang W; Li Q; Wang Z; Yang X Sci Rep; 2023 Mar; 13(1):3661. PubMed ID: 36871072 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma. Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618 [TBL] [Abstract][Full Text] [Related]
17. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Yuan H; Liu J; Zhao L; Wu P; Chen G; Chen Q; Shen P; Yang T; Fan S; Xiao B; Jiang K Front Immunol; 2021; 12():800268. PubMed ID: 34956238 [TBL] [Abstract][Full Text] [Related]
19. Characterization of the m6A/m1A/m5C/m7G-related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA-seq and bulk RNA-seq data. Yang L; Huang Z; Deng Y; Zhang X; Lv Z; Huang H; Sun Q; Liu H; Liang H; He B; Hu F J Gene Med; 2024 Feb; 26(2):e3666. PubMed ID: 38391150 [TBL] [Abstract][Full Text] [Related]
20. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients. Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]